Suchergebnisse - "Hanley, Michael J"

PubPharm (88)

51

A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

enthalten in: Journal of clinical pharmacology | 2018

von Hanley, M. | Gupta, N. | Venkatakrishnan, K. | +6

52

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling

enthalten in: Clinical pharmacokinetics | 2017

von Gupta, N. | Diderichsen, P. | Hanley, M. | +4

53

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling

enthalten in: Clinical pharmacokinetics | 2017

von Gupta, N. | Diderichsen, P. | Hanley, M. | +4

54

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma : Clinical and Model-Based Analyses

enthalten in: Targeted oncology | 2017

von Gupta, N. | Yang, H. | Hanley, M. | +6

55

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2017

von Gupta, N. | Zhang, S. | Pusalkar, S. | +8

56

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2017

von Gupta, N. | Zhang, S. | Pusalkar, S. | +8

57

A phase I study to assess the mass balance, excretion, and pharmacokinetics of [14C]-ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2017

von Gupta, N. | Zhang, S. | Pusalkar, S. | +8

58

Population Pharmacokinetic Analysis of Bortezomib in Pediatric Leukemia Patients : Model-Based Support for Body Surface Area-Based Dosing Over the 2- to 16-Year Age Range

enthalten in: Journal of clinical pharmacology | 2017

von Hanley, M. | Mould, D. | Taylor, T. | +10

59

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

enthalten in: Targeted oncology | 2017

von Gupta, N. | Yang, H. | Hanley, M. | +6

60

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses

enthalten in: Targeted oncology | 2017

von Gupta, N. | Yang, H. | Hanley, M. | +6